Susan J. Schniepp - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Susan J. Schniepp


Susan J. Schniepp is a Pharmtech editorial advisory board (EAB) member

Susan J. Schniepp
Vice-President, OSO Biopharmaceuticals

Susan Schniepp has more than 28 years of experience in quality assurance for both the food and pharmaceutical industries. She has a degree in microbiology from Northern Illinois University and began her career in 1980 as a microbiologist in the food industry for Quaker Oats and M&M/Mars. In 1984, she began working for Searle Pharmaceuticals, and in 2000 she began working for Abbott Laboratories. In 2007, she formed her own consulting firm specializing in training, quality systems, technical writing, and standards interpretations. During her career in industry she had responsibilities for complaints, labeling, validation, documentation, and other quality systems, with a primary focus on establishing communications with compendial authorities.

Schniepp joined PDA in 2000 when she began working for Abbott Laboratories. She has presented at a number of PDA meetings and participated on a number of committees including the Joint Regulatory Conference Steering Committee, RAQC, Program Advisory Board, Technical Books Advisory Board, and The Membership Committee. In 2007, she was the recipient of PDA’s Distinguished Author Award for Understanding the United States Pharmacopeia and the National Formulary: Demystifying the Standards-Setting Process.

In addition to her PDA activities, Schniepp is chair of USP’s Monograph Development – Psychiatrics and Psychoactives Expert Committee for the 2005–2010 revision cycle, in addition to serving on the Council of Experts Executive Committee from 2005–2007. She is active in the Generic Pharmaceutical Association and founded both the Midwest and Western Compendial Discussion Groups.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here